article thumbnail

Researchers reveal regenerative potential of the thymus

Drug Discovery World

Roberta Ragazzini, Postdoctoral Research Associate at the Crick and UCL, and first author of the paper, said: “It’s paradoxical that stem cells in the thymus – an organ which reduces in size as we get older – regenerate just as much as those in the skin – an organ which replaces itself every three weeks.

Research 147
article thumbnail

A research team searches for every gene that helps tumors evade immunotherapy

Broad Institute

By Allessandra DiCorato October 11, 2023 In 2011, Robert Manguso was working in a cell biology lab when his mother was diagnosed with Merkel cell carcinoma, a rare and aggressive skin cancer. They are used to treat cancers including melanoma and non-small cell lung cancer, but work only for a small fraction of patients.

Research 137
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Patient-derived organoids in disease modelling

Drug Target Review

This is particularly pertinent in immune-based cell therapies like CAR-T, where animals do not mimic the human immune response. Nikki drives adoption of 3D cellular models of human disease by applying her expertise in cell biology to drug discovery and high-throughput screening.

Disease 121
article thumbnail

CAR-NK cells: promising for cancer therapy

Drug Target Review

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 117
article thumbnail

Delivering on the promise of gene editing

Drug Discovery World

As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific.

DNA 130
article thumbnail

NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&D and Jeffrey Weber as Chief Scientific Advisor

The Pharma Data

About NexImmune NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response that mimics natural biology. . GAITHERSBURG, Md.,

article thumbnail

Who are the AACR Scientific Achievement Award winners?

Drug Discovery World

He is being recognised for his fundamental discoveries dedicated to characterising the genetic drivers of human B-cell lymphomas and for uncovering new avenues for cancer prevention and therapy that have been routinely exploited clinically to diagnose and determine novel therapeutic strategies for B-cell lymphoma.